Join the DDA or

Carbagen (carbamazepine) shortage alert

Clinical advice for switching patients

January 31st 2019

Tagged: Clinical guidance news Dispensary guidance news

By Ailsa Colquhoun

Mylan has informed the Department of Health and Social Care that 200mg and 400mg, and  200mg and 400mg modified release Carbagen (carbamazepine) tablets will be unavailable until mid-late 2019.

Patients currently prescribed Carbagen tablets by brand will therefore need to be switched to an alternative brand of carbamazepine tablets during this time.

Tegretol (carbamazepine) may be considered for alternative supply during this time, and there is a clinical memo to support clinicians in prioritising and switching patients. Clinicians are reminded of the risk of clinically relevant differences between different manufacturers’ products, even when the pharmaceutical forms are the same and bioequivalence has been shown.